Current Report Filing (8-k)
June 05 2019 - 5:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2019
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36279
|
|
75-3175693
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
4 Stamford Plaza
107 Elm Street, 9
th
Floor
Stamford, Connecticut
|
|
|
|
06902
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
|
Registrants telephone number, including area code: (203)
406-3700
|
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2.):
|
|
|
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
☐
|
|
Soliciting material pursuant to Rule
14a-12
under the
Exchange Act (17 CFR
240.14a-12)
|
|
|
|
☐
|
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
|
☐
|
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
Common stock, par value $0.001 per share
|
|
CARA
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
On June 4, 2019, Cara Therapeutics, Inc. (the Company) held its Annual Meeting of Stockholders (Annual Meeting).
At the Annual Meeting, the Companys stockholders voted on the two proposals set forth below. A more detailed description of each proposal is set forth in the Companys Proxy Statement filed with the Securities and Exchange Commission on
April 24, 2019.
Proposal 1 Election of Directors
Dr. Jeffrey L. Ives and Mr. Christopher Posner were each elected to serve as a director of the Companys Board of Directors
until the 2022 Annual Meeting of Stockholders and until his successor is duly elected or until his earlier resignation or removal, by the following votes:
|
|
|
|
|
|
|
Nominee
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
Jeffrey L. Ives, Ph.D.
|
|
10,383,585
|
|
5,345,664
|
|
15,714,667
|
Christopher Posner
|
|
15,641,126
|
|
88,123
|
|
15,714,667
|
Proposal 2 Ratification of the Selection of Independent Registered Public Accounting Firm
The stockholders ratified the selection of Ernst & Young LLP as the Companys independent registered public accounting firm for
the year ending December 31, 2019, by the following votes:
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Votes Abstain
|
31,147,675
|
|
216,461
|
|
79,780
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
CARA THERAPEUTICS, INC.
|
|
|
By:
|
|
/s/ Mani Mohindru
|
|
|
Mani Mohindru, Ph.D.
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial and Accounting Officer)
|
Date: June 5, 2019
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024